File photo/NBD

On August 27, Sanofi reportedly temporarily halted the supply and sale of its trivalent and quadrivalent flu vaccines in China.

This decision comes after ongoing stability assessments revealed a decline in the efficacy of these vaccines for the 2024-2025 flu season, said Sanofi.

Although there are no signs or evidence indicating any issues with the safety and effectiveness of the vaccines currently on the market, Sanofi is taking this preventive measure to ensure the highest standards. The flu vaccines that have already been distributed and used this year have passed all regulatory approvals and meet all legal and national drug standards, according to Yicai.